Literature DB >> 23316936

Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

Mikhail I Papisov1, Vasily V Belov, Kimberley S Gannon.   

Abstract

Presently, there are no effective treatments for several diseases involving the CNS, which is protected by the blood-brain, blood-CSF, and blood-arachnoid barriers. Traversing any of these barriers is difficult, especially for macromolecular drugs and particulates. However, there is significant experimental evidence that large molecules can be delivered to the CNS through the cerebrospinal fluid (CSF). The flux of the interstitial fluid in the CNS parenchyma, as well as the macro flux of CSF in the leptomeningeal space, are believed to be generally opposite to the desirable direction of CNS-targeted drug delivery. On the other hand, the available data suggest that the layer of pia mater lining the CNS surface is not continuous, and the continuity of the leptomeningeal space (LMS) with the perivascular spaces penetrating into the parenchyma provides an unexplored avenue for drug transport deep into the brain via CSF. The published data generally do not support the view that macromolecule transport from the LMS to CNS is hindered by the interstitial and CSF fluxes. The data strongly suggest that leptomeningeal transport depends on the location and volume of the administered bolus and consists of four processes: (i) pulsation-assisted convectional transport of the solutes with CSF, (ii) active "pumping" of CSF into the periarterial spaces, (iii) solute transport from the latter to and within the parenchyma, and (iv) neuronal uptake and axonal transport. The final outcome will depend on the drug molecule behavior in each of these processes, which have not been studied systematically. The data available to date suggest that many macromolecules and nanoparticles can be delivered to CNS in biologically significant amounts (>1% of the administered dose); mechanistic investigation of macromolecule and particle behavior in CSF may result in a significantly more efficient leptomeningeal drug delivery than previously thought.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23316936      PMCID: PMC3646927          DOI: 10.1021/mp300474m

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  121 in total

1.  Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis.

Authors:  Y Okuda; S Sakoda; H Fujimura; S Nagata; T Yanagihara; C C Bernard
Journal:  Biochem Biophys Res Commun       Date:  2000-08-18       Impact factor: 3.575

Review 2.  Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells.

Authors:  Serguei V Vinogradov; Tatiana K Bronich; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2002-01-17       Impact factor: 15.470

Review 3.  Biopharmaceutical drug targeting to the brain.

Authors:  William M Pardridge
Journal:  J Drug Target       Date:  2010-04       Impact factor: 5.121

Review 4.  Development of hydrocephalus and classical hypothesis of cerebrospinal fluid hydrodynamics: facts and illusions.

Authors:  D Orešković; M Klarica
Journal:  Prog Neurobiol       Date:  2011-05-27       Impact factor: 11.685

5.  The meninges in human development.

Authors:  R O'Rahilly; F Müller
Journal:  J Neuropathol Exp Neurol       Date:  1986-09       Impact factor: 3.685

6.  Tracing the bulk outflow route of cerebrospinal fluid by transmission and scanning electron microscopy.

Authors:  R Tripathi
Journal:  Brain Res       Date:  1974-11-22       Impact factor: 3.252

Review 7.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

8.  Continuous intrathecal baclofen for severe spasticity.

Authors:  R D Penn; J S Kroin
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

Review 9.  Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.

Authors:  K M Hemsley; J J Hopwood
Journal:  Int J Clin Pharmacol Ther       Date:  2009       Impact factor: 1.366

10.  Therapeutic efficacy of a polymeric micellar doxorubicin infused by convection-enhanced delivery against intracranial 9L brain tumor models.

Authors:  Tomoo Inoue; Yoji Yamashita; Masamichi Nishihara; Shinichiro Sugiyama; Yukihiko Sonoda; Toshihiro Kumabe; Masayuki Yokoyama; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2008-08-28       Impact factor: 12.300

View more
  37 in total

1.  Characterization of the discrepancies between four-dimensional phase-contrast magnetic resonance imaging and in-silico simulations of cerebrospinal fluid dynamics.

Authors:  Soroush Heidari Pahlavian; Alexander C Bunck; Francis Loth; R Shane Tubbs; Theresia Yiallourou; Jan Robert Kroeger; Walter Heindel; Bryn A Martin
Journal:  J Biomech Eng       Date:  2015-02-20       Impact factor: 2.097

2.  Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery.

Authors:  Daniel A Wolf; Jacob Y Hesterman; Jenna M Sullivan; Kelly D Orcutt; Matthew D Silva; Merryl Lobo; Tyler Wellman; Jack Hoppin; Ajay Verma
Journal:  JCI Insight       Date:  2016-02-25

3.  Anthropomorphic Model of Intrathecal Cerebrospinal Fluid Dynamics Within the Spinal Subarachnoid Space: Spinal Cord Nerve Roots Increase Steady-Streaming.

Authors:  Mohammadreza Khani; Lucas R Sass; Tao Xing; M Keith Sharp; Olivier Balédent; Bryn A Martin
Journal:  J Biomech Eng       Date:  2018-08-01       Impact factor: 2.097

Review 4.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

5.  Assessing Cerebrospinal Fluid Flow Dynamics in Pediatric Patients with Central Nervous System Tumors Treated with Intraventricular Radioimmunotherapy.

Authors:  Kim Kramer; Maria Donzelli; Emmanuela Nwora; Neeta Pandit-Taskar
Journal:  J Nucl Med       Date:  2020-01-31       Impact factor: 10.057

Review 6.  Enhancement of drug permeability across blood brain barrier using nanoparticles in meningitis.

Authors:  Keerthi G S Nair; Velmurugan Ramaiyan; Sathesh Kumar Sukumaran
Journal:  Inflammopharmacology       Date:  2018-03-26       Impact factor: 4.473

7.  Evidence that meningeal mast cells can worsen stroke pathology in mice.

Authors:  Ahmet Arac; Michele A Grimbaldeston; Andrew R B Nepomuceno; Oluwatobi Olayiwola; Marta P Pereira; Yasuhiro Nishiyama; Anna Tsykin; Gregory J Goodall; Ulrich Schlecht; Hannes Vogel; Mindy Tsai; Stephen J Galli; Tonya M Bliss; Gary K Steinberg
Journal:  Am J Pathol       Date:  2014-09       Impact factor: 4.307

8.  Nonuniform Moving Boundary Method for Computational Fluid Dynamics Simulation of Intrathecal Cerebrospinal Flow Distribution in a Cynomolgus Monkey.

Authors:  Mohammadreza Khani; Tao Xing; Christina Gibbs; John N Oshinski; Gregory R Stewart; Jillynne R Zeller; Bryn A Martin
Journal:  J Biomech Eng       Date:  2017-08-01       Impact factor: 2.097

Review 9.  Imaging the Perivascular Space as a Potential Biomarker of Neurovascular and Neurodegenerative Diseases.

Authors:  Joel Ramirez; Courtney Berezuk; Alicia A McNeely; Fuqiang Gao; JoAnne McLaurin; Sandra E Black
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

Review 10.  Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier.

Authors:  Stephen B Hladky; Margery A Barrand
Journal:  Fluids Barriers CNS       Date:  2018-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.